Exclusive License. North America has herein granted an exclusive license to the Operator together with its Know-how, technical experience and training program for the exploitation of the Insituform process within and throughout the defined Territory. If, despite North America's best efforts to maintain the exclusivity of its licenses and defend its Patent, Trademark and Copyright protections, such exclusivity and/or protections should be terminated for any reason whatsoever, the Operator hereunder is nevertheless obligated to comply in full with each and every term and condition of this agreement, including, but not limited to, the payment of Royalties to North America and the maintenance of high standards of quality and service.
Exclusive License. Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).
Exclusive License. If a Data Contributor exercises its option to negotiate an exclusive license, Recipient agrees to negotiate exclusively in good faith with such Data Contributor, for up to one hundredeighty(180) days or suchmutuallyagreeablelongerperiod, regardingcommerciallyreasonable termsforan exclusive, worldwide, fee-bearing license, including theright to sublicense throughmultipletiers, forthe Data Contributoranditsaffiliates to make, havemade, use, sell or otherwise dispose of the subject mat- ter of the New Intellectual Property or productsincorporating the subject matter of the New Intellectual Property subject to any non-exclusive licenses granted in section 4(c) above. In the event that Data Con- tributor doesnotexerciseitsoption to negotiate an exclusive license, or in theeventRecipientand Data Contributor fail to agree to commercially reasonable exclusive license terms following good faith negotia- tion, Recipient may negotiatefurther non-exclusive licensetermswiththirdparties. Any such terms shall be consistent with the non-exclusive license that Recipient agrees to grant to Data Contributor in Section 4(c) above. Shouldanyterms be agreed with a thirdparty in accordance withthissection, then for five
Exclusive License. Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants to Licensee an exclusive, worldwide, royalty-bearing license, sublicensable solely in accordance with Sections 2.2 and 2.3, under the Patent Rights solely (a) to identify, discover, develop, make, have made, use, market, offer for sale, sell, have sold and import Type I and Type II Licensed Products and (b) to perform Licensed Services; provided, however, that:
Exclusive License. Unit members shall have exclusive license to works owned by them but may through their written permission, provide a non-exclusive license to the District or to other unit members to use the work in a manner prescribed in the written permission by the unit members who own the works. If the work is considered a “Work for Hire,” the copyright shall be owned by the District and may be assigned or licensed by the District without the consent or permission of the unit member.
Exclusive License. Corixa hereby grants to Introgen an exclusive, worldwide license, with the right to sublicense under the Licensed Technology solely to research, make, have made, use, sell, offer to sell, have sold, import and otherwise distribute Licensed Products, practice any method, process or procedure, or otherwise exploit the Licensed Technology; provided that such license shall in each case be limited to the Field (the “Exclusive License”).
Exclusive License. Subject to the terms and conditions of this Agreement, on an Allogene Target-by-Allogene Target basis, Cellectis hereby grants to Allogene and its Affiliates an exclusive (even as to Cellectis) license under the Licensed Cellectis Intellectual Property (excluding [***] Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Allogene Licensed Products in the Field in the Territory, with the right to sublicense as provided in Section 4.1.4 (the “License”).
Exclusive License. As of the Effective Date, Neose hereby grants, and agrees to grant, to Novo an exclusive (even as to Neose), royalty-bearing license under the Neose Technology in the Field of Use during the Term, (i) to conduct research, sample, develop (including clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New Products. Such license does not permit Novo (x) to practice or use the Neose Technology outside the Field of Use or (y) to sublicense any of its rights without the prior written approval of Neose, except as provided in Section 5.1.2.
Exclusive License. An exclusive, worldwide, royalty-bearing license, with the right to sublicense through multiple tiers, under the Blocking Arsanis Patents, Other Arsanis Patents and Arsanis Know-How, in each case, solely to develop, make, have made, use, sell, have sold, offer for sale and import RSV Antibodies and Products (excluding Fully-Paid Products) in the Field; provided, however, that, to the extent that Blocking Arsanis Patents, Other Arsanis Patents or Arsanis Know-How includes Patents or Know-How licensed to Arsanis by a Third Party that is subject to royalty or milestone payment obligations to such Third Party with respect to any RSV Antibody or Product, then Arsanis shall so notify Adimab, together with a true, complete and correct description of such royalty and milestone payment obligations, and the inclusion of such Patents or Know-How in the Blocking Arsanis Patents, Other Arsanis Patents or Arsanis Know-How (as applicable) shall be subject to Adimab’s agreeing in writing to pay, and promptly paying, all royalty and milestone payments that become due to such Third Party by reason of the development, manufacture, use, sale, offer for sale or import of RSV Antibodies and Products by or on behalf of Adimab or its Affiliates, licensees or sublicensees (in addition to the mutually agreed compensation payable to Arsanis for the grant of rights described in this Section 9.5(b)(iv) (Exclusive Unblocking License and Regulatory Transfer to Adimab));
Exclusive License. BMPI hereby grants to Luitpold, and Luitpold hereby accepts from BMPI, subject to the terms and conditions herein specified, an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Product(s) purchased from BMPI. Notwithstanding the foregoing exclusive sublicense, BMPI reserves the right to use the Licensed Products for purposes of conducting trials and other tests with respect to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system on animals in studies related to development of safety and efficacy information needed for the technology for human use and applications provided BMPI will share all such information with Luitpold. Any rights not expressly granted pursuant to this Agreement shall be reserved to BMPI. Except pursuant to the terms of this Agreement, BMPI will not exercise any rights under the Licensed Patent Rights.